ACADIA Pharmaceuticals Inc. ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc.

ACAD

Rangering i aksjer #4649
ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily... ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.
Aksjekurs
$18.95
Sist synkronisert: 2026-10-16
Markedsverdi
$3.26B
Endring (1 dag)
-3.86%
Endring (1 år)
-9.29%
Land
US
Handel ACADIA Pharmaceuticals Inc. (ACAD)

Kategori

Healthcare
Driftsmargin for ACADIA Pharmaceuticals Inc. (ACAD)
Driftsmargin per October 2026 TTM: 7.59%
Ifølge ACADIA Pharmaceuticals Inc. sine siste økonomiske rapporter og aksjekurs er selskapets nåværende driftsmargin (TTM) 7.59%. Ved slutten av 2023 hadde selskapet en driftsmargin på -10.10%.
Historikk for driftsmargin for ACADIA Pharmaceuticals Inc. fra 2000 til 2026
Driftsmargin ved slutten av hvert år
År Driftsmargin Endre
2026 (TTM) 7.59% -68.51%
2024 24.10% -338.61%
2023 -10.10% -76.64%
2022 -43.23% 22.81%
2021 -35.20% -45.74%
2020 -64.87% -10.78%
2019 -72.71% -34.23%
2018 -110.56% -52.77%
2017 -234.11% -85.13%
2016 -1,574.14% -99.42%
2015 -269,855.74% 247.34%
2014 -77,691.67% 2,222.82%
2013 -3,344.72% 685.81%
2012 -425.64% -61.50%
2011 -1,105.56% -3,186.43%
2010 35.82% -105.04%
2009 -710.55% -83.13%
2008 -4,212.45% 407.95%
2007 -829.31% 37.50%
2006 -603.15% 84.56%
2005 -326.81% -42.34%
2004 -566.76% 204.35%
2003 -186.22% -7.44%
2002 -201.19% -51.10%
2001 -411.39% 57.42%
2000 -261.34% 0.00%
Driftsmargin for lignende selskaper eller konkurrenter
Selskap Driftsmargin Forskjell i driftsmargin Land
38.59% -94.92%
US
-149.01% -119.63%
US
25.57% -96.63%
AU
0.00% -
CH
28.81% -96.20%
NL
Hva er selskapets Driftsmargin?
Driftsmargin er en nøkkelindikator for å vurdere lønnsomheten til et selskap. Høyere Driftsmargins er vanligvis bedre, da de viser at selskapet kan selge sine produkter eller tjenester for mye mer enn produksjonskostnadene. Driftsmargin beregnes ved å dele selskapets inntjening med inntektene.